These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33462295)

  • 1. Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques.
    Gillis RB; Solomon HV; Govada L; Oldham NJ; Dinu V; Jiwani SI; Gyasi-Antwi P; Coffey F; Meal A; Morgan PS; Harding SE; Helliwell JR; Chayen NE; Adams GG
    Sci Rep; 2021 Jan; 11(1):1737. PubMed ID: 33462295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quaternary structure of insulin glargine and glulisine under formulation conditions.
    Nagel N; Graewert MA; Gao M; Heyse W; Jeffries CM; Svergun D; Berchtold H
    Biophys Chem; 2019 Oct; 253():106226. PubMed ID: 31376619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin glulisine complementing basal insulins: a review of structure and activity.
    Becker RH
    Diabetes Technol Ther; 2007 Feb; 9(1):109-21. PubMed ID: 17316105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure, Aggregation, and Activity of a Covalent Insulin Dimer Formed During Storage of Neutral Formulation of Human Insulin.
    Hjorth CF; Norrman M; Wahlund PO; Benie AJ; Petersen BO; Jessen CM; Pedersen TÅ; Vestergaard K; Steensgaard DB; Pedersen JS; Naver H; Hubálek F; Poulsen C; Otzen D
    J Pharm Sci; 2016 Apr; 105(4):1376-86. PubMed ID: 26921119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
    Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
    Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the correlation between insulin activity and structural stability through introduction of the rigid A6-A11 bond.
    Ong SC; Belgi A; van Lierop B; Delaine C; Andrikopoulos S; MacRaild CA; Norton RS; Haworth NL; Robinson AJ; Forbes BE
    J Biol Chem; 2018 Jul; 293(30):11928-11943. PubMed ID: 29899115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application.
    Helms KL; Kelley KW
    Ann Pharmacother; 2009 Apr; 43(4):658-68. PubMed ID: 19336657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small angle X-ray scattering-based elucidation of the self-association mechanism of human insulin analogue lys(B29)(N(ε)ω-carboxyheptadecanoyl) des(B30).
    Jensen MH; Wahlund PO; Toft KN; Jacobsen JK; Steensgaard DB; van de Weert M; Havelund S; Vestergaard B
    Biochemistry; 2013 Jan; 52(2):282-94. PubMed ID: 23256662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin glulisine.
    Cox SL
    Drugs Today (Barc); 2005 Jul; 41(7):433-40. PubMed ID: 16193096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
    Teska BM; Alarcón J; Pettis RJ; Randolph TW; Carpenter JF
    J Pharm Sci; 2014 Aug; 103(8):2255-67. PubMed ID: 24909933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.
    Garg SK; Ellis SL; Ulrich H
    Expert Opin Pharmacother; 2005 Apr; 6(4):643-51. PubMed ID: 15934890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues.
    Kamal AD; Bain SC
    Expert Opin Drug Saf; 2007 Jan; 6(1):5-7. PubMed ID: 17181446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of insulin analogues therapeutically available to patients.
    Adams GG; Meal A; Morgan PS; Alzahrani QE; Zobel H; Lithgo R; Kok MS; Besong DTM; Jiwani SI; Ballance S; Harding SE; Chayen N; Gillis RB
    PLoS One; 2018; 13(3):e0195010. PubMed ID: 29596514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glulisine.
    Robinson DM; Wellington K
    Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Insulin analogues: modifications in the structure, molecular and metabolic consequences].
    de Luis DA; Romero E
    Semergen; 2013; 39(1):34-40. PubMed ID: 23517895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
    Home PD
    Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec.
    Steensgaard DB; Schluckebier G; Strauss HM; Norrman M; Thomsen JK; Friderichsen AV; Havelund S; Jonassen I
    Biochemistry; 2013 Jan; 52(2):295-309. PubMed ID: 23256685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues.
    Whittingham JL; Edwards DJ; Antson AA; Clarkson JM; Dodson GG
    Biochemistry; 1998 Aug; 37(33):11516-23. PubMed ID: 9708987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.